Anteris Technologies Global Corp當前公司基本面數據相對健康,增長潛力穩定。當前估值合理,在醫療設備與耗材行業排名96/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價16.50。中期看,股價處於上升通道。近一個月,市場表現很強,技術面評分較高,但很強的走勢沒有得到基本面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。
Anteris Technologies Global Corp評分
相關信息
行業排名
96 / 208
全市場排名
226 / 4582
所屬行業
醫療設備與耗材
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
4
分析師
買入
評級
16.500
目標均價
+245.91%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議
Anteris Technologies Global Corp亮點
亮點風險
Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
公司代碼AVR
公司Anteris Technologies Global Corp
CEOPaterson (Wayne G)
網址https://anteristech.com/
常見問題
Anteris Technologies Global Corp(AVR)的當前股價是多少?
Anteris Technologies Global Corp(AVR)的當前股價是 5.320。
Anteris Technologies Global Corp 的股票代碼是什麼?
Anteris Technologies Global Corp的股票代碼是AVR。
Anteris Technologies Global Corp股票的52週最高點是多少?
Anteris Technologies Global Corp股票的52週最高點是8.790。
Anteris Technologies Global Corp股票的52週最低點是多少?
Anteris Technologies Global Corp股票的52週最低點是2.340。
Anteris Technologies Global Corp的市值是多少?
Anteris Technologies Global Corp的市值是191.85M。
Anteris Technologies Global Corp的淨利潤是多少?
Anteris Technologies Global Corp的淨利潤為-76.29M。
現在Anteris Technologies Global Corp(AVR)的股票是買入、持有還是賣出?
根據分析師評級,Anteris Technologies Global Corp(AVR)的總體評級為買入,目標價格為16.500。
Anteris Technologies Global Corp(AVR)股票的每股收益(EPS TTM)是多少
Anteris Technologies Global Corp(AVR)股票的每股收益(EPS TTM)是-2.341。